Nutriband Inc. (NTRBW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Orlando, FL, アメリカ. 現CEOは Gareth Sheridan.
NTRBW を有する IPO日 2021-10-01, 3 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $13.1M.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
